tbuckley/cabot-search huggingface dataset:
Increased β <sub>2</sub> -adrenergic signaling promotes fracture healing through callus neovascularization in mice
Authors: Denise Jahn, Paul Richard Knapstein, Ellen Otto, Paul Köhli, Jan Sevecke, Frank Graef, Christine Graffmann, Melanie Fuchs, Shan Jiang, Mayla Rickert, Cordula Erdmann, Jessika Appelt, Lawik Revend, Quin Küttner, Jason Witte, Adibeh Rahmani, Georg Duda, Weixin Xie, Antonia Donat, Thorsten Schinke, Andranik Ivanov, Mireille Ngokingha Tchouto, Dieter Beule, Karl-Heinz Frosch, Anke Baranowsky, Serafeim Tsitsilonis, Johannes Keller
Journal: Science Translational Medicine (2024)

Traumatic brain injury (TBI) leads to skeletal changes, including bone loss in the unfractured skeleton, and paradoxically accelerates healing of bone fractures; however, the mechanisms remain unclear. TBI is associated with a hyperadrenergic state characterized by increased norepinephrine release. Here, we identified the β 2 -adrenergic receptor (ADRB2) as a mediator of skeletal changes in response to increased norepinephrine. In a murine model of femoral osteotomy combined with cortical impact brain injury, TBI was associated with ADRB2-dependent enhanced fracture healing compared with osteotomy alone. In the unfractured 12-week-old mouse skeleton, ADRB2 was required for TBI-induced decrease in bone formation and increased bone resorption. Adult 30-week-old mice had higher bone concentrations of norepinephrine, and ADRB2 expression was associated with decreased bone volume in the unfractured skeleton and better fracture healing in the injured skeleton. Norepinephrine stimulated expression of vascular endothelial growth factor A and calcitonin gene–related peptide-α (αCGRP) in periosteal cells through ADRB2, promoting formation of osteogenic type-H vessels in the fracture callus. Both ADRB2 and αCGRP were required for the beneficial effect of TBI on bone repair. Adult mice deficient in ADRB2 without TBI developed fracture nonunion despite high bone formation in uninjured bone. Blocking ADRB2 with propranolol impaired fracture healing in mice, whereas the ADRB2 agonist formoterol promoted fracture healing by regulating callus neovascularization. A retrospective cohort analysis of 72 patients with long bone fractures indicated improved callus formation in 36 patients treated with intravenous norepinephrine. These findings suggest that ADRB2 is a potential therapeutic target for promoting bone healing.
Deep learning assists detection of esophageal cancer and precursor lesions in a prospective, randomized controlled study
Authors: Shao-wei Li, Li-hui Zhang, Yue Cai, Xian-bin Zhou, Xin-yu Fu, Ya-qi Song, Shi-wen Xu, Shen-ping Tang, Ren-quan Luo, Qin Huang, Ling-ling Yan, Sai-qin He, Yu Zhang, Jun Wang, Shu-qiong Ge, Bin-bin Gu, Jin-bang Peng, Yi Wang, Li-na Fang, Wei-dan Wu, Wen-guang Ye, Min Zhu, Ding-hai Luo, Xiu-xiu Jin, Hai-deng Yang, Jing-jing Zhou, Zhen-zhen Wang, Jian-fen Wu, Qiao-qiao Qin, Yan-di Lu, Fei Wang, Ya-hong Chen, Xia Chen, Shan-jing Xu, Tao-Hsin Tung, Chen-wen Luo, Li-ping Ye, Hong-gang Yu, Xin-li Mao
Journal: Science Translational Medicine (2024)

Endoscopy is the primary modality for detecting asymptomatic esophageal squamous cell carcinoma (ESCC) and precancerous lesions. Improving detection rate remains challenging. We developed a system based on deep convolutional neural networks (CNNs) for detecting esophageal cancer and precancerous lesions [high-risk esophageal lesions (HrELs)] and validated its efficacy in improving HrEL detection rate in clinical practice (trial registration ChiCTR2100044126 at www.chictr.org.cn ). Between April 2021 and March 2022, 3117 patients ≥50 years old were consecutively recruited from Taizhou Hospital, Zhejiang Province, and randomly assigned 1:1 to an experimental group (CNN-assisted endoscopy) or a control group (unassisted endoscopy) based on block randomization. The primary endpoint was the HrEL detection rate. In the intention-to-treat population, the HrEL detection rate [28 of 1556 (1.8%)] was significantly higher in the experimental group than in the control group [14 of 1561 (0.9%), P = 0.029], and the experimental group detection rate was twice that of the control group. Similar findings were observed between the experimental and control groups [28 of 1524 (1.9%) versus 13 of 1534 (0.9%), respectively; P = 0.021]. The system’s sensitivity, specificity, and accuracy for detecting HrELs were 89.7, 98.5, and 98.2%, respectively. No adverse events occurred. The proposed system thus improved HrEL detection rate during endoscopy and was safe. Deep learning assistance may enhance early diagnosis and treatment of esophageal cancer and may become a useful tool for esophageal cancer screening.
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia
Authors: Nandita Noronha, Chantal Durette, Maxime Cahuzac, Bianca E Silva, Justine Courtois, Juliette Humeau, Allan Sauvat, Marie-Pierre Hardy, Krystel Vincent, Jean-Philippe Laverdure, Joël Lanoix, Frédéric Baron, Pierre Thibault, Claude Perreault, Gregory Ehx
Journal: Leukemia (2024)

Abstract The hypomethylating agent 5-azacytidine (AZA) is the first-line treatment for AML patients unfit for intensive chemotherapy. The effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, evidence supporting higher ERE MAPs presentation after AZA treatment is lacking. Therefore, using proteogenomics, we examined the impact of AZA on the repertoire of MAPs and their source transcripts. AZA-treated AML upregulated both CTA and ERE transcripts, but only CTA MAPs were presented at greater levels. Upregulated ERE transcripts triggered innate immune responses against double-stranded RNAs but were degraded by autophagy, and not processed into MAPs. Autophagy resulted from the formation of protein aggregates caused by AZA-dependent inhibition of DNMT2. Autophagy inhibition had an additive effect with AZA on AML cell proliferation and survival, increased ERE levels, increased pro-inflammatory responses, and generated immunogenic tumor-specific ERE-derived MAPs. Finally, autophagy was associated with a lower abundance of CD8 + T-cell markers in AML patients expressing high levels of EREs. This work demonstrates that AZA-induced EREs are degraded by autophagy and shows that inhibiting autophagy can improve the immune recognition of AML blasts in treated patients.
Size‐Dependent Blue Emission from Europium‐Doped Strontium Fluoride Nanoscintillators for X‐Ray‐Activated Photodynamic Therapy
Authors: Natasha Policei Marques, Mileni M. Isikawa, Zeinaf Muradova, Toby Morris, Ross Berbeco, Eder J. Guidelli
Journal: Advanced Healthcare Materials (2024)

Abstract Successful implementation of X‐ray‐activated photodynamic therapy (X‐PDT) is challenging because most photosensitizers (PSs) absorb light in the blue region, but few nanoscintillators produce efficient blue scintillation. Here, efficient blue‐emitting SrF 2 :Eu scintillating nanoparticles (ScNPs) are developed. The optimized synthesis conditions result in cubic nanoparticles with ≈32 nm diameter and blue emission at 416 nm. Coating them with the meso‐tetra( n ‐methyl‐4‐pyridyl) porphyrin (TMPyP) in a core–shell structure (SrF@TMPyP) results in maximum singlet oxygen ( 1 O 2 ) generation upon X‐ray irradiation for nanoparticles with 6TMPyP depositions (SrF@6TMPyP). The 1 O 2 generation is directly proportional to the dose, does not vary in the low‐energy X‐ray range (48–160 kVp), but is 21% higher when irradiated with low‐energy X‐rays than irradiations with higher energy gamma rays. In the clonogenic assay, cancer cells treated with SrF@6TMPyP and exposed to X‐rays present a significantly reduced survival fraction compared to the controls. The SrF 2 :Eu ScNPs and their conjugates stand out as tunable nanoplatforms for X‐PDT due to the efficient blue emission from the SrF 2 :Eu cores; the ability to adjust the scintillation emission in terms of color and intensity by controlling the nanoparticle size; the efficient 1 O 2 production when conjugated to a PS and the efficacy of killing cancer cells.
Three-Year Outcomes of Oral Antibiotics vs Intravenous and Oral Antibiotics for Uncomplicated Acute Appendicitis
Authors: Liisa Selänne, Jussi Haijanen, Suvi Sippola, Saija Hurme, Tero Rautio, Pia Nordström, Tuomo Rantanen, Tarja Pinta, Imre Ilves, Anne Mattila, Jukka Rintala, Harri Marttila, Sanna Meriläinen, Johanna Laukkarinen, Eeva-Liisa Sävelä, Hannu Paajanen, Juha Grönroos, Paulina Salminen
Journal: JAMA Surgery (2024)

Current short-term evidence has shown that uncomplicated acute appendicitis can be treated successfully with oral antibiotics alone, but longer-term results are lacking.
Dominant negative OTULIN-related autoinflammatory syndrome
Authors: Sophia Davidson, Yuri Shibata, Sophie Collard, Hongyu Zheng, Klara Kong, June M. Sun, Pawat Laohamonthonkul, Anthony Cerra, Tobias Kratina, Margaret W.Y. Li, Carolyn Russell, Anna van Beek, Edwin P. Kirk, Rebecca Walsh, Jubran Alqanatish, Abdullah Almojali, Wafaa Alsuwairi, Abdulrahman Alrasheed, Najoua Lalaoui, Paul E. Gray, David Komander, Seth L. Masters
Journal: The Journal of Experimental Medicine (2024)

OTU deubiquitinase with linear linkage specificity (OTULIN) regulates inflammation and cell death by deubiquitinating linear ubiquitin chains generated by the linear ubiquitin chain assembly complex (LUBAC). Biallelic loss-of-function mutations causes OTULIN-related autoinflammatory syndrome (ORAS), while OTULIN haploinsuffiency has not been associated with spontaneous inflammation. However, herein, we identify two patients with the heterozygous mutation p.Cys129Ser in OTULIN. Consistent with ORAS, we observed accumulation of linear ubiquitin chains, increased sensitivity to TNF-induced death, and dysregulation of inflammatory signaling in patient cells. While the C129S mutation did not affect OTULIN protein stability or binding capacity to LUBAC and linear ubiquitin chains, it did ablate OTULIN deubiquitinase activity. Loss of activity facilitated the accumulation of autoubiquitin chains on LUBAC. Altered ubiquitination of LUBAC inhibits its recruitment to the TNF receptor signaling complex, promoting TNF-induced cell death and disease pathology. By reporting the first dominant negative mutation driving ORAS, this study expands our clinical understanding of OTULIN-associated pathology.
Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium
Authors: Sebastiaan Dhont, Gitte van den Acker, Tim van Loon, Frederik H. Verbrugge, Jan Verwerft, Sébastien Deferm, Timothy W. Churchill, Wilfried Mullens, Joost Lumens, Philippe B. Bertrand
Journal: European Journal of Heart Failure (2024)
Treatment of Keratosis Lichenoides Chronica With Upadacitinib
Authors: Jingyi Tang, Fang Liu, Wenjun Liao, Guannan Zhu
Journal: JAMA Dermatology (2024)

This case report describes a 30-year-old man presenting with 1-year history of nonitchy red papules and patches who was subsequently treated with upadacitinib.
Sex Differences in Autism Heritability and Likelihood
Authors: Alex Tsompanidis, Varun Warrier, Simon Baron-Cohen
Journal: JAMA Psychiatry (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Outcomes of the Main Residency Match for Applicants With Disability
Authors: Mytien Nguyen, Lisa M. Meeks, Zoie C. Sheets, Rylee Betchkal, Karina Pereira-Lima, Christopher J. Moreland, Dowin H. Boatright
Journal: JAMA (2024)

This cohort study assesses match rates of US applicants with and without disability into specialty residence programs.
Pain Scores as Secondary Outcomes—Opioid Reduction Studies—Reply
Authors: Nina A. Cooperman, Shou-En Lu, Eric L. Garland
Journal: JAMA Psychiatry (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN Trials
Authors: Muhammad Atif Zahoor, Joshua B. Feld, Hsing-Hua Sylvia Lin, Alexander I. Mosa, Loghman Salimzadeh, Robert P. Perrillo, Raymond T. Chung, Kathleen B. Schwarz, Harry L.A. Janssen, Adam J. Gehring, Jordan J. Feld
Journal: Hepatology (2024)

Background &amp; Aims: Pegylated interferon-α (PegIFNα) is of limited utility during immunotolerant or immune active phases of chronic hepatitis B infection but is being explored as part of new cure regimens. Low/absent levels of IFNα found in some patients receiving treatment are associated with limited/no virological responses. The study aimed to determine if sera from participants inhibit IFNα activity and/or contain therapy-induced anti-IFNα antibodies. Approach &amp; Results: Pre-treatment, on-treatment, and post-treatment sera from 61 immunotolerant trial participants on PegIFNα/entecavir therapy and 88 immune active trial participants on PegIFNα/tenofovir therapy were screened for anti-IFNα antibodies by indirect ELISA. The neutralization capacity of antibodies was measured by preincubation of sera±recombinant human IFNα added to Huh7 cells with the measurement of interferon-stimulated gene (ISG)-induction by qPCR. Correlations between serum-induced ISG inhibition, presence, and titer of anti-IFNα antibodies and virological responses were evaluated. Preincubation of on-treatment serum from 26 immunotolerant (43%) and 13 immune active (15%) participants with recombinant-human IFNα markedly blunted ISG-induction in Huh7 cells. The degree of ISG inhibition correlated with IFNα antibody titer ( p &lt; 0.0001; r = 0.87). On-treatment development of anti-IFNα neutralizing antibodies (nAbs) was associated with reduced quantitative HBsAg and qHBeAg declines ( p &lt; 0.05) and inhibited IFNα bioactivity to 240 weeks after PegIFNα cessation. Children developed anti-IFNα nAbs more frequently than adults ( p = 0.004) but nAbs in children had less impact on virological responses. Conclusions: The development of anti-IFNα nAbs during PegIFNα treatment diminishes responses to antiviral therapy. Understanding how and why anti-IFNα antibodies develop may allow for the optimization of IFN-based therapy, which is critical given its renewed use in HBV-cure strategies.
Errors in SDs in Results and Table 4
Journal: JAMA Network Open (2024)

titled "Effect of Remote Monitoring on Discharge to Home, Return to Activity, and Rehospitalization After Hip and Knee Arthroplasty: A Randomized Clinical Trial," 1 published December 21, 2020, there were errors in the presentation of SDs.For the mean (SD) given in Results as "833 (177)," the SD should have been "1303."In Table 4, the SD value given as "280" should have been "1372," the value given as "227" should have been "1244," and the value given as "177" should have been "1303."This article was corrected.
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial
Authors: Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lopes, Michael J Davies, Phillip Banks, Bertram Pitt, Ph. Gabriel Steg
Journal: European Journal of Heart Failure (2024)
Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk
Authors: Yi Li, Jing Li, Bin Wang, Quanmin Jing, Yujie Zeng, Aijie Hou, Zhifang Wang, Aijun Liu, Jinliang Zhang, Yaojun Zhang, Ping Zhang, Daming Jiang, Bin Liu, Jiamao Fan, Jun Zhang, Li Li, Guohai Su, Ming Yang, Weihong Jiang, Peng Qu, Hesong Zeng, Lu Li, Miaohan Qiu, Leisheng Ru, Shaoliang Chen, Yujie Zhou, Shubin Qiao, Gregg W. Stone, Dominick J. Angiolillo, Yaling Han, Ping Yang, Gang Wu, Yang Zheng, Liyou Sui, Jianbin Gong , Jie Mi, Hong Chen, Ruiyan Zhang, Xi Su , Xingsheng Zhao , Zhujun Chen , Biao Xu, Hanjun Pei , Na Li , Hongliang Cong, Jinghua Liu, Xiling Shou , Fengde Wang , Da Yin , Xiaofeng Hu, Jian An , Chunyu Zeng, Jincheng Guo , Genshan Ma , Xinfu Zhou, Lefeng Wang , Qin Qin, Qiutang Zeng , Shuangbin Li , Yi Zheng, Zuyi Yuan, Qing Yang , Gang Liu , Xianxian Zhao, Lingge Kong , Jifu Li , Tianchang Li , Ruiping Zhao, Hong Wang, Chunjian Li , Yanbo Jiang,  Likun Ma , Ping Hou, Zixin Zhang , Junxia Li    , Zhixiong Zhong , Zhimin Du  , Zhiyong Wang , Xuezhi Chen, Longzhe Jin, Changqian Wang, Chengxing Shen, Gang Zhao, Xiaohui Liu, Yongjun Li , Chuanyu Gao , Biao Cheng , Jiang Wang, Yuanzhe Jin , Qun Jin, Songjian He, Zhaofen Zheng, Yukun Luo, Yingwu Liu  , Taohong Hu, Zhanying Han, Weiheng Wu, Hua Wang, Yitong Ma, Jianhong Tao, Haiming Shi, Fucheng Sun, Yansong Guo, Hongyi Wu , Li Feng  , Jianhua Zhu, Xubo Shi, Xiaodong Li 
Journal: JAMA Cardiology (2024)

Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).
Measures of Referral vs Receipt of Social Services Among Patients With Health-Related Social Needs
Authors: Fred S. Johnson, Eugenia R. McPeek Hinz, David Regan, Raman Nohria, Gene Moon, Susan E. Spratt
Journal: JAMA Network Open (2024)

This cohort study compares measures of referral vs receipt in evaluating social resource platform outcomes among patients with health-related social needs.
Blinding, Placebo Effect, and GRADE Methodology—What Is Relevant?
Authors: Nathan Bontekoning, Hannah Groenen, Marja A. Boermeester
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Prevalence of Mental Health Disorders Among Individuals Experiencing Homelessness
Authors: Rebecca Barry, Jennifer Anderson, Lan Tran, Anees Bahji, Gina Dimitropoulos, S. Monty Ghosh, Julia Kirkham, Geoffrey Messier, Scott B. Patten, Katherine Rittenbach, Dallas Seitz
Journal: JAMA Psychiatry (2024)

Several factors may place people with mental health disorders, including substance use disorders, at increased risk of experiencing homelessness and experiencing homelessness may also increase the risk of developing mental health disorders. Meta-analyses examining the prevalence of mental health disorders among people experiencing homelessness globally are lacking.
Potential Role of Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Rosacea Flushing and Erythema
Authors: John S. Barbieri
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal